Overall, whether the change in aHR assessed in terms of cumulative dose or duration of exposure to spironolactone, we observed a decreasing trend in prostate cancer risk and an increasing trend in renal cancer risk.
← all excerpts
Association of spironolactone use with risk of urinary tract cancer in the general population: A matched population-based cohort study.
1
—
—